Prostate Cancer Treatment: Complete Clinical Guide, Benefits & Recovery

Clinical Overview: Understanding Prostate Cancer Treatment

Prostate Cancer Treatment represents a cornerstone clinical program at Spica Healthcare — Grover Hospital, Bathinda. Supervised directly by Dr. Neha Gupta (Director & Senior Medical Oncologist), this evidence-based pathway integrates sub-millimeter surgical precision, advanced intraoperative 3D navigation, ISO Class-100 Laminar Airflow surgical suites, and personalized accelerated rehabilitation to restore function, eliminate pain, and maximize long-term treatment longevity.

In South-Western Punjab and adjoining regions of Haryana and Rajasthan, patients frequently encounter delayed clinical diagnoses or generalized approaches that fail to address anatomical nuances. At Spica Healthcare, every patient undergoes rigorous digital staging, ensuring that surgical interventions or targeted medical therapies are customized to individual biomechanics and oncological requirements.

Clinical Indications: When is Prostate Cancer Treatment Recommended?

• Newly diagnosed localized, locally advanced, or metastatic adenocarcinoma of the prostate.

• Metastatic hormone-sensitive prostate cancer (mHSPC) requiring triplet therapy (ADT + ARAT + Docetaxel).

• Metastatic castration-resistant prostate cancer (mCRPC) with HRR/BRCA mutations requiring Olaparib.

• mCRPC progressing on novel hormonal agents eligible for 177Lu-PSMA-617 radioligand therapy.

Step-by-Step Surgical & Clinical Pathway at Grover Hospital

Step 1: PSMA PET-CT & Gleason Staging

Serum Total PSA, Gleason score histology review, and 68Ga-PSMA PET-CT whole-body staging.

Step 2: Genomic HRR Molecular Profiling

HRR gene panel testing (BRCA1, BRCA2, ATM, CHEK2) for targeted therapy eligibility.

Step 3: Surgical, Radiation or Triplet Care

Multidisciplinary treatment execution: Robotic radical prostatectomy, IMRT radiation, or triplet systemic oncology.

Step 4: Long-Term PSA Surveillance

Continuous PSA kinetics tracking and bone density optimization for long-term health.

Director's Signature Innovation: Advanced Multimodal Prostate Cancer Oncology

Dr. Neha Gupta leads comprehensive multidisciplinary Prostate Oncology at Spica Healthcare. Integrating 68Ga-PSMA PET-CT molecular imaging, upfront triplet therapy (ADT + Docetaxel + Darolutamide/Abiraterone - ARASENS protocol) for high-volume metastatic disease, germline/somatic homologous recombination repair (HRR) gene testing for targeted PARP inhibitors (Olaparib), and advanced 177Lutetium-PSMA-617 radioligand theranostics for refractory disease, prostate cancer is controlled with high precision and multi-year survival.

✔ Upfront Triplet Systemic Therapy: High survival benefit in newly diagnosed metastatic prostate cancer

✔ HRR / BRCA Genomic Testing: Identifies candidates for targeted oral PARP inhibitors (Olaparib/Rucaparib)

✔ 177Lu-PSMA Radioligand Therapy: Molecularly targeted radiation directly seeking out metastatic cells

✔ Bone-Targeted Dual Therapy: Proactive prevention of skeletal events with Zoledronic acid/Denosumab

Recovery Timeline & Functional Milestones

Phase 1: PSMA PET-CT Staging & Genetics (Day 1 – 7)

Serum Total PSA, 68Ga-PSMA PET-CT whole-body scan, and HRR/BRCA genetic panel initiation.

Phase 2: Active Systemic Induction (Month 1 – 6)

Initiation of ADT + novel oral ARAT ± Docetaxel chemotherapy cycles in Daycare suite.

Phase 3: Deep Remission Maintenance (Month 6 – 12)

PSA nadir verification, bone health maintenance, and continuous oral targeted maintenance.

Phase 4: Long-Term Disease Control (Year 1 – Long Term)

Long-term 3-monthly PSA tracking, PSMA PET-CT monitoring, and sustained disease control.

Frequently Asked Clinical Questions (FAQs)

What is a PSMA PET-CT scan and why is it superior in prostate cancer?

PSMA (Prostate-Specific Membrane Antigen) is a protein overexpressed on prostate cancer cells. A PSMA PET-CT scan uses a radioactive tracer that binds specifically to PSMA, detecting microscopic prostate cancer spread anywhere in the body with unprecedented clarity far earlier than standard CT or bone scans.

What is 177Lutetium-PSMA therapy for advanced prostate cancer?

Lutetium-177 PSMA is an advanced targeted radioligand therapy. A radioactive molecule seeks out and attaches to PSMA receptors on prostate cancer cells throughout the body, delivering lethal localized beta radiation directly to the tumor while sparing healthy surrounding tissues.

Is Prostate Cancer Treatment cashless under Ayushman Bharat?

Yes, prostate cancer systemic therapies, ADT injections, targeted ARATs, chemotherapy, and inpatient admissions at Grover Hospital Bathinda are covered 100% cashless under PM-JAY Ayushman Bharat and 30+ private TPAs.

100% Cashless Insurance & PM-JAY Ayushman Bharat Empanelment

At Spica Healthcare — Grover Hospital Bathinda, Prostate Cancer Treatment is fully covered under the Government of India's PM-JAY Ayushman Bharat scheme and over 30+ leading private insurance TPAs. Our on-campus insurance coordinator handles all pre-authorization documentation directly with your insurance company, eliminating financial delays. Families can also share digital DICOM CDs and biopsy reports via WhatsApp (+91 95013 73003) for an urgent surgical review.